Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy

Journal of Bone and Mineral Research

Volumn 27, Issue 8, 2012, Pages 1757-1772

  Sabbagh, Yves ^a   Graciolli, Fabiana Giorgeti ^b   O'Brien, Stephen ^a   Tang, Wen ^a   Dos Reis, Luciene MacHado ^b   Ryan, Susan ^a   Phillips, Lucy ^a   Boulanger, Joseph ^a   Song, Wenping ^a   Bracken, Christina ^a   Liu, Shiguang ^a   Ledbetter, Steven ^a   Dechow, Paul ^c   Canziani, Maria Eugenia F ^d   Carvalho, Aluizio B ^d   Jorgetti, Vanda ^b   Moyses, Rosa M A ^b   Schiavi, Susan C ^a  

^a SANOFI   (France)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c BAYLOR COLLEGE OF DENTISTRY   (United States)

^d FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

OSTEOCYTE; RENAL OSTEODYSTROPHY; WNT CATENIN

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ATRIAL NATRIURETIC FACTOR; BETA CATENIN; BRAIN NATRIURETIC PEPTIDE; CATHEPSIN K; COLLAGEN TYPE 1; DICKKOPF 1 PROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; OSTEOPROTEGERIN; PHOSPHOETHANOLAMINE; SCLEROSTIN; SECRETED FRIZZLED RELATED PROTEIN 4; TRANSGELIN; WNT PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL CALCIFICATION; BONE MINERALIZATION; BONE REMODELING; CALCIUM BLOOD LEVEL; CELL ACTIVITY; CELL FUNCTION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; HYPERPHOSPHATEMIA; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCYTE; PROTEIN EXPRESSION; RENAL OSTEODYSTROPHY; SIGNAL TRANSDUCTION; WILD TYPE;

ANIMALS; BIOPSY; BONE AND BONES; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; CARDIOVASCULAR ABNORMALITIES; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; MUTATION; OSTEOCLASTS; OSTEOCYTES; PROTEIN-SERINE-THREONINE KINASES; RENAL OSTEODYSTROPHY; VASCULAR CALCIFICATION; WNT SIGNALING PATHWAY;

EID: 84864152751     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1630     Document Type: Article

References (80)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS,. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298: 2038-47.
2. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H,. The burden of kidney disease: improving global outcomes. Kidney Int. 2004; 66: 1310-4.
3. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH,. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004; 164: 659-63.
4. Watanabe R, Lemos MM, Manfredi SR, Draibe SA, Canziani ME,. Impact of cardiovascular calcification in nondialyzed patients after 24 months of follow-up. Clin J Am Soc Nephrol. 2010; 5: 189-94.
5. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G,. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006; 69: 1945-53.
6. Moe SM,. Definition and classification of renal osteodystrophy and chronic kidney disease-mineral bone disorder (CKD-MBD). In:, Olgaard K, Salusky IB, Silver J, editors. The spectrum of mineral and bone disorders in chronic kidney disease. New York: Oxford University; 2010. p 1-14.
7. Malluche HH, Mawad H, Monier-Faugere MC,. The importance of bone health in end-stage renal disease: out of the frying pan, into the fire? Nephrol Dial Transplant. 2004; 19 (Suppl 1): i9-13.
8. Hruska KA, Mathew S, Lund RJ, Memon I, Saab G,. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Semin Nephrol. 2009; 29: 156-65.
9. Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH,. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res. 2008; 23: 1850-8.
10. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC,. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943-51.
11. Boukhris R, Becker KL,. Calcification of the aorta and osteoporosis. A roentgenographic study. JAMA. 1972; 219: 1307-11.
12. Banks LM, Lees B, MacSweeney JE, Stevenson JC,. Effect of degenerative spinal and aortic calcification on bone density measurements in post-menopausal women: links between osteoporosis and cardiovascular disease? Eur J Clin Invest. 1994; 24: 813-7.
13. Hak AE, Pols HA, van Hemert AM, Hofman A, Witteman JC,. Progression of aortic calcification is associated with metacarpal bone loss during menopause: a population-based longitudinal study. Arterioscler Thromb Vasc Biol. 2000; 20: 1926-31.
14. Kiel DP, Kauppila LI, Cupples LA, Hannan MT, O'Donnell CJ, Wilson PW,. Bone loss and the progression of abdominal aortic calcification over a 25 year period: the Framingham Heart Study. Calcif Tissue Int. 2001; 68: 271-6.
15. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC,. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996; 27: 394-401.
16. Ho LT, Sprague SM,. Renal osteodystrophy in chronic renal failure. Semin Nephrol. 2002; 22: 488-93.
17. Price PA, Buckley JR, Williamson MK,. The amino bisphosphonate ibandronate prevents vitamin D toxicity and inhibits vitamin D-induced calcification of arteries, cartilage, lungs and kidneys in rats. J Nutr. 2001; 131: 2910-5.
18. Price PA, Faus SA, Williamson MK,. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001; 21: 817-24.
19. Price PA, June HH, Buckley JR, Williamson MK,. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001; 21: 1610-6.
20. Lomashvili KA, Monier-Faugere MC, Wang X, Malluche HH, O'Neill WC,. Effect of bisphosphonates on vascular calcification and bone metabolism in experimental renal failure. Kidney Int. 2009; 75: 617-25.
21. Gonzalez EA, Lund RJ, Martin KJ, McCartney JE, Tondravi MM, Sampath TK, Hruska KA,. Treatment of a murine model of high-turnover renal osteodystrophy by exogenous BMP-7. Kidney Int. 2002; 61: 1322-31.
22. Lund RJ, Davies MR, Brown AJ, Hruska KA,. Successful treatment of an adynamic bone disorder with bone morphogenetic protein-7 in a renal ablation model. J Am Soc Nephrol. 2004; 15: 359-69.
23. Barreto DV, Barreto Fde C, Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME,. Association of changes in bone remodeling and coronary calcification in hemodialysis patients: a prospective study. Am J Kidney Dis. 2008; 52: 1139-50.
24. Giachelli CM,. Inducers and inhibitors of biomineralization: lessons from pathological calcification. Orthod Craniofac Res. 2005; 8: 229-31.
25. Wallin R, Wajih N, Greenwood GT, Sane DC,. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001; 21: 274-301.
26. Moe SM, Chen NX, Seifert MF, Sinders RM, Duan D, Chen X, Liang Y, Radcliff JS, White KE, Gattone VH 2nd., A rat model of chronic kidney disease-mineral bone disorder. Kidney Int. 2009; 75: 176-84.
27. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009; (113): S1-130.
28. Smith LA, Bukanov NO, Husson H, Russo RJ, Barry TC, Taylor AL, Beier DR, Ibraghimov-Beskrovnaya O,. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol. 2006; 17: 2821-31.
29. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarrõ F, Valdivielso JM, Fernández E,. Mineral metabolism parameters throughout chronic kidney disease stages 1-5-achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007; 22: 1171-6.
30. Bonewald LF,. The amazing osteocyte. J Bone Miner Res. 2011; 26: 229-38.
31. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ, Bonewald LF, Kodama T, Wutz A, Wagner EF, Penninger JM, Takayanagi H,. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat Med. 2011; 17: 1231-4.
32. Glass DA 2nd, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, Taketo MM, Long F, McMahon AP, Lang RA, Karsenty G,. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005; 8: 751-64.
33. Holmen SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO,. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem. 2005; 280: 21162-8.
34. Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M,. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010; 30: 3071-85.
35. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR,. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987; 2: 595-610.
36. Tomiyama C, Carvalho AB, Higa A, Jorgetti V, Draibe SA, Canziani ME,. Coronary calcification is associated with lower bone formation rate in CKD patients not yet in dialysis treatment. J Bone Miner Res. 2010; 25: 499-504.
37. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA, Moyses RM, Neves KR, Jorgetti V, Blair A, Guiberteau R, Fernandes Canziani ME,. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int. 2005; 67: 1576-82.
38. Barreto DV, Barreto Fde C, de Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, Moyses RM, Neves KR, Jorgetti V, Miname M, Santos RD, Canziani ME,. Phosphate binder impact on bone remodeling and coronary calcification-results from the BRiC study. Nephron Clin Pract. 2008; 110: c273-83.
39. Gomes SA, dos Reis LM, de Oliveira IB, Noronha IL, Jorgetti V, Heilberg IP,. Usefulness of a quick decalcification of bone sections embedded in methyl methacrylate[corrected]: an improved method for immunohistochemistry. J Bone Miner Metab. 2008; 26: 110-3.
40. Mehrotra R, Adler S,. Coronary artery calcification in nondialyzed patients with chronic kidney diseases. Am J Kidney Dis. 2005; 45: 963.
41. Mehrotra R, Budoff M, Christenson P, Ipp E, Takasu J, Gupta A, Norris K, Adler S,. Determinants of coronary artery calcification in diabetics with and without nephropathy. Kidney Int. 2004; 66: 2022-31.
42. Menon V, Sarnak MJ,. The epidemiology of chronic kidney disease stages 1 to 4 and cardiovascular disease: a high-risk combination. Am J Kidney Dis. 2005; 45: 223-32.
43. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW,. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108: 2154-69.
44. Foley RN, Parfrey PS, Sarnak MJ,. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol. 1998; 9: S16-23.
45. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY,. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305.
46. Moe SM, Chen NX,. Pathophysiology of vascular calcification in chronic kidney disease. Circ Res. 2004; 95: 560-7.
47. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, Salem DN, Levey AS, Sarnak MJ,. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis. 2004; 44: 198-206.
48. Parfitt AM,. Renal bone disease: a new conceptual framework for the interpretation of bone histomorphometry. Curr Opin Nephrol Hypertens. 2003; 12: 387-403.
49. Felsenfeld A, Torres A,. Bone histomorphometry in renal osteodystrophy. In:, Olgaard K, Silver J, Salusky IB, editors. The spectrum of mineral and bone disorders in chronic kidney disease. 2nd edition. New York: Oxford University Press; 2010.
50. Kurz P, Tsobanelis T, Brunkhorst R, Roth P, Werner E, Schoeppe W, Vlachojannis J,. Calcium kinetic studies in patients on CAPD: improvement of secondary hyperparathyroidism without concomitant improvement of calcium turnover. Perit Dial Int. 1997; 17: 59-65.
51. Parfitt AM,. Misconceptions (3): calcium leaves bone only by resorption and enters only by formation. Bone. 2003; 33: 259-63.
52. Malluche HH, Ritz E, Lange HP, Kutschera L, Hodgson M, Seiffert U, Schoeppe W,. Bone histology in incipient and advanced renal failure. Kidney Int. 1976; 9: 355-62.
53. Moe SM, Radcliffe JS, White KE, Gattone VH, Seifert MF, Chen X, Aldridge B, Chen NX,. The pathophysiology of early stage chronic kidney disease-mineral bone disorder (CKDMBD) and response to phosphate binders in the rat. J Bone Miner Res. 2011 Nov; 26 (11): 2672-81.
54. Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, David V, Hong Y, Quarles LD,. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res. Epub 2011 Sep 28. DOI: 10.1002/jbmr.516.
55. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Juppner H, Wolf M,. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol. 2005; 16: 2205-15.
56. Pavik I, Jaeger P, Kistler AD, Poster D, Krauer F, Cavelti-Weder C, Rentsch KM, Wuthrich RP, Serra AL,. Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate. Kidney Int. 2011; 79: 234-40.
57. Giachelli CM, Speer MY, Li X, Rajachar RM, Yang H,. Regulation of vascular calcification: roles of phosphate and osteopontin. Circ Res. 2005; 96: 717-22.
58. Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L,. Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy. Am J Kidney Dis. 2004; 43: 558-65.
59. Dusso AS, Brown AJ, Slatopolsky E,. Vitamin D. Am J Physiol Renal Physiol. 2005; 289: F8-28.
60. Solal ME, Sebert JL, Boudailliez B, Marie A, Moriniere P, Gueris J, Bouillon R, Fournier A,. Comparison of intact, midregion, and carboxy terminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab. 1991; 73: 516-24.
61. Andress DL,. Bone and mineral guidelines for patients with chronic kidney disease: a call for revision. Clin J Am Soc Nephrol. 2008; 3: 179-83.
62. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y,. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminum toxicity. Am J Kidney Dis. 1995; 26: 836-44.
63. Qi Q, Monier-Faugere MC, Geng Z, Malluche HH,. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995; 26: 622-31.
64. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, de Bonis E, Darias E, Gonzalez-Posada JM, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int. 1995; 47: 1434-42.
65. Barreto FC, Barreto DV, Moyses RM, Neves KR, Canziani ME, Draibe SA, Jorgetti V, Carvalho AB,. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int. 2008; 73: 771-7.
66. Ferreira A, Frazao JM, Monier-Faugere MC, Gil C, Galvao J, Oliveira C, Baldaia J, Rodrigues I, Santos C, Ribeiro S, Hoenger RM, Duggal A, Malluche HH,. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol. 2008; 19: 405-12.
67. Drueke TB,. Is parathyroid hormone measurement useful for the diagnosis of renal bone disease? Kidney Int. 2008; 73: 674-6.
68. Wijenayaka AR, Kogawa M, Lim HP, Bonewald LF, Findlay DM, Atkins GJ,. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011; 6: e25900.
69. Cejka D, Herberth J, Branscum AJ, Fardo DW, Monier-Faugere MC, Diarra D, Haas M, Malluche HH,. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011; 6: 877-82.
70. Case N, Rubin J,. Beta-catenin-a supporting role in the skeleton. J Cell Biochem. 2010; 110: 545-53.
71. Rocha LA, Higa A, Barreto FC, dos Reis LM, Jorgetti V, Draibe SA, Carvalho AB,. Variant of adynamic bone disease in hemodialysis patients: fact or fiction? Am J Kidney Dis. 2006; 48: 430-6.
72. Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O'Brien CA, Manolagas SC, Jilka RL,. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005; 146: 4577-83.
73. Keller H, Kneissel M,. SOST is a target gene for PTH in bone. Bone. 2005; 37: 148-58.
74. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, Allen MR, Robling AG, Bouxsein M, Schipani E, Turner CH, Jilka RL, Weinstein RS, Manolagas SC, Bellido T,. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS One. 2008; 3: e2942.
75. Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, He X, Nie S, Chang C, Cao X,. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev. 2008; 22: 2968-79.
76. Kramer I, Loots GG, Studer A, Keller H, Kneissel M,. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res. 2010; 25: 178-89.
77. Sohara E, Luo Y, Zhang J, Manning DK, Beier DR, Zhou J,. Nek8 regulates the expression and localization of polycystin-1 and polycystin-2. J Am Soc Nephrol. 2008; 19: 469-76.
78. Xiao Z, Zhang S, Magenheimer BS, Luo J, Quarles LD,. Polycystin-1 regulates skeletogenesis through stimulation of the osteoblast-specific transcription factor RUNX2-II. J Biol Chem. 2008; 283: 12624-34.
79. Xiao Z, Zhang S, Mahlios J, Zhou G, Magenheimer BS, Guo D, Dallas SL, Maser R, Calvet JP, Bonewald L, Quarles LD,. Cilia-like structures and polycystin-1 in osteoblasts/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression. J Biol Chem. 2006; 281: 30884-95.
80. Wallingford JB, Mitchell B,. Strange as it may seem: the many links between Wnt signalling, planar cell polarity, and cilia. Genes Dev. 2011; 25: 201-13.